Sage touts positive early signals in Alzheimer's. Will they be able to repeat it in a blinded study?
Sage Therapeutics on Friday uncorked what it sees as some positive — albeit early, and unblinded — data suggesting its lead neuropsychiatric drug led to improvements in Alzheimer’s patients. Now the real test will be seeing if those results hold up in a larger, blinded group.
“The study was designed first and foremost for safety, tolerability and PK,” Aaron Koenig, Sage’s VP of early clinical development, told Endpoints News.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 153,800+ biopharma pros reading Endpoints daily — and it's free.